{"filing":{"accession_number":"0001104659-26-095437","cik":"0001953926","ticker":"ZBIO","company_name":"Zenas BioPharma, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-12","primary_document":"tm2622871d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_8k.htm"},"events":[{"id":27469,"run_id":25041,"accession_number":"0001104659-26-095437","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Zenas BioPharma reported Q2 2026 financial results for the quarter ended June 30, 2026, disclosing revenue of $1.0 million, R\u0026D expenses of $62.9 million, G\u0026A expenses of $15.7 million, net loss of $111.5 million, and cash position of $673.9 million.","company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29033,"accession_number":"0001104659-26-095437","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 13, 2026. The press release discloses quarterly financial results including revenue ($1.0 million), R\u0026D expenses ($62.9 million), G\u0026A expenses ($15.7 million), and net loss ($111.5 million), along with cash position ($673.9 million). The filing explicitly states \"Zenas BioPharma Reports Second Quarter 2026 Financial Results\" and the press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:07:57.305205+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":27470,"run_id":25041,"accession_number":"0001104659-26-095437","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The Board appointed Christy J. Oliger as a Class II director effective September 1, 2026, with assignment to two Board committees. Ms. Oliger brings 30+ years of biopharmaceutical commercial and operating experience, including senior roles at Genentech leading multi-billion-dollar product portfolios, which is material to the company's advancement toward commercialization.","company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29034,"accession_number":"0001104659-26-095437","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The Item 5.02 disclosure centers on the Board's appointment of Christy J. Oliger as a Class II director effective September 1, 2026, with assignment to two Board committees. While the section also mentions director compensation (stock options and cash), the principal disclosed action is the appointment itself. Ms. Oliger's extensive biopharmaceutical commercial and operating experience (30+ years, including senior roles at Genentech leading multi-billion-dollar product portfolios) is material to a clinical-stage company advancing toward commercialization, making this a material executive appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:07:57.305205+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29033,"accession_number":"0001104659-26-095437","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 13, 2026. The press release discloses quarterly financial results including revenue ($1.0 million), R\u0026D expenses ($62.9 million), G\u0026A expenses ($15.7 million), and net loss ($111.5 million), along with cash position ($673.9 million). The filing explicitly states \"Zenas BioPharma Reports Second Quarter 2026 Financial Results\" and the press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:07:57.305205+00:00","company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","filing_date":"2026-08-13"},{"id":29034,"accession_number":"0001104659-26-095437","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The Item 5.02 disclosure centers on the Board's appointment of Christy J. Oliger as a Class II director effective September 1, 2026, with assignment to two Board committees. While the section also mentions director compensation (stock options and cash), the principal disclosed action is the appointment itself. Ms. Oliger's extensive biopharmaceutical commercial and operating experience (30+ years, including senior roles at Genentech leading multi-billion-dollar product portfolios) is material to a clinical-stage company advancing toward commercialization, making this a material executive appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:07:57.305205+00:00","company_name":"Zenas BioPharma, Inc.","ticker":"ZBIO","filing_date":"2026-08-13"}]}